| METS | BPLAE | MPM | Healthy subjects |
---|---|---|---|---|
Lymphocyte populations a | ||||
  Total CD3+ T-cells | 80.5 (76–87.5) | 85.2 (81–90.1) | 77 (69–84) | 85 (80–88) |
  CD4+ T-cells | 63.2 (53.8-72) | 63.5 (52.5-72) | 54.2 (44–62.5) | 30.0 (21–32) |
  CD8+ T-cells | 19 (15–25) | 22 (16.4-29) | 25 (19.2-33.5) | 53 (45–59) |
  CD4+/CD8+ ratio | 3.8 (2.6-4.8) | 3.2 (2.2-4.5) | 2.2 (1.5-2.9) | 0.59 (0.48-0.67) |
  Treg (CD4low+CD25bright+)b | 4.4 (3–5.9) | 4.4 (2.4-5.3) | 3.1 | 2.2 (1.6-3.7) |
  NK cells (CD3─CD56+) | 3.5 (2.2-7.5) | 2.8 (2–4) | 10 (3.4-12.5) | 16.0 (12.4-24.1) |
  → % of CD16 + NK cells | 30 (20–59) | 18 (1–35) | 26 (14–54) | 6% (3–8) |
CD4 + T cell subsets b | ||||
  Naïve | 22.7 (14.7-29) | 25.7 (14.3-37) | 11.2 (3.8-27) | 1.6 (1–2.4) |
  TCM | 47.4 (30–62) | 53.5 (42.9-60) | 40.5 (27.5-51) | 13.1 (9.8-19.6) |
  TEM | 21 (11.4-38.2) | 18.6 (10.2-22) | 19.2 (9.3-32) | 85.1 (77.2-88.9) |
  TTD | 0.6 (0.3-1.4) | 1.3 (0.5-1.7) | 0.8 (0.3-1.6) | 0.7 (0.3-1) |
CD8 + T cell subsets b | ||||
  Naïve | 15.2 (7.1-37.3) | 26 (22–43.4) | 11.2 (3.9-29.6) | 1.4 (0.9-2.1) |
  TCM | 22.1 (12–34.7) | 27.4 (17.8-44) | 11.6 (7.2-28.3) | 2.3 (1.6-4.7) |
  TEM | 19.7 (4.3-45.3) | 16.1 (10.7-36) | 18.6 (5.6-49.2) | 84.7 (83.1-87) |
  TTD | 12.7 (5.6-22.3) | 13.7 (8–22.9) | 7.4 (2.4-20.7) | 9.5 (8.5-12.2) |